Zobrazeno 1 - 10
of 5 141
pro vyhledávání: '"Dienemann, H"'
Autor:
Szymanowska-Narloch, A, Jassem, E, Skrzypski, M, Muley, T, Meister, M, Dienemann, H, Taron, M, Rosell, R, Rzepko, R, Jarząb, M, Marjański, T, Pawłowski, R, Rzyman, W, Jassem, J
Publikováno v:
In Advances in Medical Sciences 1 December 2013 58(2):196-206
Autor:
Gassler N; Department of Pathology, University of Heidelberg, Heidelberg, Germany., Zhang C; Clinical Cooperation Unit Molecular Oncology, German Cancer Research Center, Im Neuenheimer Feld 280, 69120, Heidelberg, Germany., Wenger T; Clinical Cooperation Unit Molecular Oncology, German Cancer Research Center, Im Neuenheimer Feld 280, 69120, Heidelberg, Germany., Schnabel PA; Department of Pathology, University of Heidelberg, Heidelberg, Germany., Dienemann H; Thoraxklinik-Heidelberg, University of Heidelberg, Heidelberg, Germany., Debatin K-; Children's Hospital, University of Ulm, Ulm, Germany., Mattern J; Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center, Heidelberg, Germany., Herr I; Clinical Cooperation Unit Molecular Oncology, German Cancer Research Center, Im Neuenheimer Feld 280, 69120, Heidelberg, Germany. i.herr@uni-heidelberg.de.; Children's Hospital, University of Ulm, Ulm, Germany. i.herr@uni-heidelberg.de.
Publikováno v:
British journal of cancer [Br J Cancer] 2023 Oct; Vol. 129 (8), pp. 1363.
PD-L1, as assessed by immunohistochemistry, is a predictive biomarker for immuno-oncology treatment in lung cancer. Different scoring methods have been used to assess its status, resulting in a wide range of positivity rates. We use the European Thor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______2127::f02fc25a4341656e52192cf3c9795bab
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3121206
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3121206
Autor:
Kopp, R., Weidenhagen, R., Reinmiedl, J., Müller, C., Fürst, H., Bittmann, I., Dienemann, H., Hatz, R.
Publikováno v:
In European Journal of Surgical Oncology 2006 32(3):329-334
Publikováno v:
Diagnostic Pathology, Vol 2, Iss Suppl 1, p S3 (2007)
Externí odkaz:
https://doaj.org/article/c497161d7955469fac09d41eefe320ba
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Introduction: The reported prevalence of ALK receptor tyrosine kinase gene (ALK) rearrangement in NSCLC ranges from 2% to 7%. The primary standard diagnostic method is fluorescence in situ hybridization (FISH). Recently, immunohistochemistry (IHC) ha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______2127::2a7593a2d3ab8d4d6ce01fff07c107d0
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3107651
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3107651
Autor:
Laplana M; Division of Cancer Epigenomics, German Cancer Research Center (DKFZ), Heidelberg, Germany., Bieg M; Center for Digital Health, Berlin Institute of Health and Charité - Universitätsmedizin Berlin, Berlin, Germany.; Heidelberg Center for Personalized Oncology (DKFZ-HIPO), Heidelberg, Germany., Faltus C; Division of Cancer Epigenomics, German Cancer Research Center (DKFZ), Heidelberg, Germany.; Department of Biosciences, Allergy-Cancer-BioNano Research Centre, University of Salzburg, Salzburg, Austria., Melnik S; Division of Cancer Epigenomics, German Cancer Research Center (DKFZ), Heidelberg, Germany., Bogatyrova O; Division of Cancer Epigenomics, German Cancer Research Center (DKFZ), Heidelberg, Germany., Gu Z; Heidelberg Center for Personalized Oncology (DKFZ-HIPO), Heidelberg, Germany.; Division of Theoretical Bioinformatics, German Cancer Research Center (DKFZ), Heidelberg, Germany., Muley T; Translational Research Unit, Thoraxklinik-Heidelberg gGmbH, University of Heidelberg, Heidelberg, Germany.; Translational Lung Research Center Heidelberg (TLRC), Member of the German Center for Lung Research (DZL), Heidelberg, Germany., Meister M; Translational Research Unit, Thoraxklinik-Heidelberg gGmbH, University of Heidelberg, Heidelberg, Germany.; Translational Lung Research Center Heidelberg (TLRC), Member of the German Center for Lung Research (DZL), Heidelberg, Germany., Dienemann H; Translational Lung Research Center Heidelberg (TLRC), Member of the German Center for Lung Research (DZL), Heidelberg, Germany.; Department of Thoracic Surgery, Thoraxklinik at University Hospital Heidelberg, Heidelberg, Germany., Herpel E; Tissue Bank of the National Center for Tumor Diseases (NCT) and Institute of Pathology, Heidelberg University Hospital, Germany., Amos CI; Department of Medicine, Baylor College of Medicine, Houston, TX, United States., Schlesner M; Division of Theoretical Bioinformatics, German Cancer Research Center (DKFZ), Heidelberg, Germany.; Bioinformatics and Omics Data Analytics, German Cancer Research Center (DKFZ), Heidelberg, Germany., Eils R; Center for Digital Health, Berlin Institute of Health and Charité - Universitätsmedizin Berlin, Berlin, Germany.; Heidelberg Center for Personalized Oncology (DKFZ-HIPO), Heidelberg, Germany.; Health Data Science Unit, University Hospital Heidelberg, Heidelberg, Germany., Plass C; Division of Cancer Epigenomics, German Cancer Research Center (DKFZ), Heidelberg, Germany., Risch A; Division of Cancer Epigenomics, German Cancer Research Center (DKFZ), Heidelberg, Germany.; Department of Biosciences, Allergy-Cancer-BioNano Research Centre, University of Salzburg, Salzburg, Austria.; Translational Lung Research Center Heidelberg (TLRC), Member of the German Center for Lung Research (DZL), Heidelberg, Germany.; Cancer Cluster Salzburg, Austria.
Publikováno v:
Epigenetics [Epigenetics] 2022 Jan-Feb; Vol. 17 (2), pp. 117-132. Date of Electronic Publication: 2021 Feb 17.